Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.59 |
| ▸ | HTR1D | P28221 | 2/20 | 0.59 |
| ▸ | HTR1B | P28222 | 2/20 | 0.59 |
| ▸ | KIF11 | P52732 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR5A | P47898 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2610249 | 0.86 | HTR7 (0.56) | HTR1AHTR1DHTR1BKIF11HSD17B10 | |
| SCHEMBL14572835 | 0.86 | PDE4A (0.53) | HTR1AHTR1DHTR1BKIF11HSD17B10 | |
| SCHEMBL12120938 | 0.84 | HTR1A (0.59) | HTR1AHTR1DHTR1BHSD17B10MEN1 | |
| SCHEMBL27548934 | 0.82 | PBRM1 (0.61) | HTR1AHTR1DHTR1BKIF11HSD17B10 | |
| SCHEMBL14120820 | 0.81 | GPR84 (0.60) | KIF11HSD17B10MEN1KMT2AALDH1A1 | |
| SCHEMBL2610316 | 0.81 | HTR1A (0.61) | HTR1AHTR1DHTR1BKIF11HSD17B10 | |
| SCHEMBL18775424 | 0.81 | HTR1A (0.57) | HTR1AHTR1DHTR1BKIF11HSD17B10 | |
| SCHEMBL29951862 | 0.81 | F7 (0.60) | HTR1AHTR1DHTR1BKIF11HSD17B10 | |
| SCHEMBL6755274 | 0.79 | ALDH1A1 (0.67) | HSD17B10MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL14211119 | 0.78 | ALDH1A1 (0.56) | HTR1AHTR1DHTR1BKIF11HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170035730-A1 | PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2017-02-09 | — | — | US | disclosed |
| US-8957093-B2 | N-biphenylmethylindole modulators of PPARG | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-02-17 | — | — | US | disclosed |
| US-8748417-B2 | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-06-10 | — | — | US | disclosed |
| US-8575363-B2 | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-11-05 | — | — | US | disclosed |
| US-20130196970-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-01 | — | — | US | disclosed |
| US-20120309757-A1 | N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120101081-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196970-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, MGLL | HTR1A 852/4885HTR1D 289/4885HTR1B 413/4885 |
| US-20170035730-A1 | PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS | PPARG, PPARA, PPARD | HTR1A 2199/4885HTR1D 3262/4885HTR1B 2885/4885 |
| US-20120101081-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, MGLL | HTR1A 852/4885HTR1D 289/4885HTR1B 413/4885 |
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | PPARG, PPARA, PPARD | HTR1A 2199/4885HTR1D 3262/4885HTR1B 2885/4885 |
| US-20120309757-A1 | N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG | CDK5, CDK5R1, PPARG | HTR1A 951/4885HTR1D 2009/4885HTR1B 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.